Literature DB >> 30135071

Non-Hodgkin lymphoma.

Anna Bowzyk Al-Naeeb1, Thankamma Ajithkumar2, Sarah Behan3, Daniel James Hodson4,5.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30135071     DOI： 10.1136/bmj.k3204

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

Review 1.  The Relevance of Aurora Kinase Inhibition in Hematological Malignancies.

Authors:  Caio Bezerra Machado; Emerson Lucena DA Silva; Beatriz Maria Dias Nogueira; Jean Breno Silveira DA Silva; Manoel Odorico DE Moraes Filho; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  Cancer Diagn Progn       Date:  2021-07-03

2.  Rituximab combined with GDP regimen can effectively improve the efficacy and immune function of non-Hodgkin lymphoma.

Authors:  Chao Song; Yanli Feng; Fanmei Ge; Zhiyun Zhang; Baoxiong Su
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 3.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

4.  Cobalt (III) complex exerts anti-cancer effects on T cell lymphoma through induction of cell cycle arrest and promotion of apoptosis.

Authors:  Praveen Kumar Verma; Rishi Kant Singh; Sandeep Kumar; Alok Shukla; Sanjay Kumar; Mannu Kumar Gond; Manoj Kumar Bharty; Arbind Acharya
Journal:  Daru       Date:  2022-03-16       Impact factor: 4.088

Review 5.  MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Authors:  Chiara Cioccarelli; Barbara Molon
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

Review 6.  Maxillofacial lymphomas.

Authors:  David MacDonald; Montgomery Martin; Kerry Savage
Journal:  Br J Radiol       Date:  2021-01-06       Impact factor: 3.039

7.  Inhibition of HIF-1α by Atorvastatin During 131I-RTX Therapy in Burkitt's Lymphoma Model.

Authors:  Eun-Ho Kim; Hae Young Ko; A Ram Yu; Hyeongi Kim; Javeria Zaheer; Hyun Ji Kang; Young-Cheol Lim; Kyung Deuk Cho; Hyun-Yoo Joo; Min Kyoung Kang; Jae Jun Lee; Seung-Sook Lee; Hye Jin Kang; Sang Moo Lim; Jin Su Kim
Journal:  Cancers (Basel)       Date:  2020-05-11       Impact factor: 6.639

8.  Soluble CD40 ligand inhibits the growth of non-Hodgkin's lymphoma cells through the JNK signaling pathway.

Authors:  Zhongxin Feng; Jishi Wang
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

9.  miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration.

Authors:  Min Yue Zhang; Lu Qian Wang; Chor Sang Chim
Journal:  Cell Commun Signal       Date:  2021-05-27       Impact factor: 7.525

10.  Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017.

Authors:  Gulfaraz Khan; Christina Fitzmaurice; Mohsen Naghavi; Luai A Ahmed
Journal:  BMJ Open       Date:  2020-08-30       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.